Post by Deleted on Feb 23, 2019 18:29:53 GMT
Oppenheimer 4.5 Star analyst re-iterates on 2/21. See meeting notes below. Sounds great.
www.analystratings.com/articles/oppenheimer-thinks-polarityte-incs-stock-is-going-to-recover/?ref=tipranks
In a report released yesterday, Kevin Degeeter from Oppenheimer maintained a Buy rating on PolarityTE Inc (PTE – Research Report), with a price target of $30. The company’s shares closed yesterday at $12.22, close to its 52-week low of $11.54.
Degeeter said:
“We recently met with management of PTE. Based on the discussion we see no basis for recent weakness in PTE share price and would be buyers at current levels. On the two most pressing topics for most investors—1) understanding the pace of commercial adoption for SkinTE and 2) progress toward resolution of FDA manufacturing review—we’d note important progress including confirmation of plans to open a second manufacturing facility. The decision to move forward with additional manufacturing capacity reflects confidence in both interactions with FDA and outlook for commercial uptake, in our view. Separately, management noted discussions with potential partners are accelerating and could culminate in an ex-US agreement with material upfront payments in 2019. $30 PT.”